Dyne Therapeutics Inc

Stage 2 advancing remains intact with a clear higher-high/higher-low regime. Despite a Bullish Exhaustion signal pausing momentum, price has retraced into and is holding the rising 9/21 EMA support zone. EMAs remain stacked and sloping upward, offering a favorable dynamic support entry. We will buy now to align with the medium-term bullish trend.

• ↑Consensus Moderate Buy rating with $34.17 target implies 45.9% upside
• ↑13F ownership high at 3.47 signals strong institutional confidence
• ↓Profitability score indicates difficulty achieving sustainable margins